GSK plc (XETRA: GS7.DE) Stock Competitors & Peer Comparison
See GS7.DE's competitors and their performance on the XETRA and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GS7.DE and its XETRA peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GS7.DE | €20.60 | +25.00% | 0 | 17.31 | €1.19 | +3.79% |
| LLY.DE | €1,174.60 | +4.09% | 1.1T | 44.39 | €26.46 | +0.49% |
| JNJ.DE | €237.30 | +4.38% | 571.9B | 26.63 | €8.91 | +1.91% |
| 4AB.DE | €253.70 | +0.48% | 448.3B | 44.42 | €5.71 | +2.37% |
| 4AB.DU | €252.00 | +0.36% | 445.3B | 44.13 | €5.71 | +2.39% |
| NOVC.DE | €91.40 | -2.42% | 406.7B | 22.91 | €3.99 | +12.20% |
| 6MK.DE | €135.94 | +2.63% | 335.4B | 54.41 | €2.50 | +2.15% |
| ZEG.DE | €160.70 | +0.59% | 249.2B | 26.61 | €6.04 | +1.72% |
| AMG.DE | €400.80 | +3.21% | 216.7B | 20.79 | €19.28 | +2.16% |
| GIS.DE | €138.94 | +1.65% | 172.3B | -112.01 | -€1.24 | +2.05% |
Stock Comparison
Eli Lilly and Company (XETRA: LLY.DE)
GS7.DE vs LLY.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, LLY.DE has a market cap of 1.1T. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while LLY.DE trades at €1,174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas LLY.DE's P/E ratio is 44.39. In terms of profitability, GS7.DE's ROE is +0.26%, compared to LLY.DE's ROE of +0.93%. Regarding short-term risk, GS7.DE is more volatile compared to LLY.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check LLY.DE's competition here
Johnson & Johnson (XETRA: JNJ.DE)
GS7.DE vs JNJ.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, JNJ.DE has a market cap of 571.9B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while JNJ.DE trades at €237.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas JNJ.DE's P/E ratio is 26.63. In terms of profitability, GS7.DE's ROE is +0.26%, compared to JNJ.DE's ROE of +0.19%. Regarding short-term risk, GS7.DE is more volatile compared to JNJ.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check JNJ.DE's competition here
AbbVie Inc. (XETRA: 4AB.DE)
GS7.DE vs 4AB.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, 4AB.DE has a market cap of 448.3B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while 4AB.DE trades at €253.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas 4AB.DE's P/E ratio is 44.42. In terms of profitability, GS7.DE's ROE is +0.26%, compared to 4AB.DE's ROE of -1.37%. Regarding short-term risk, GS7.DE is more volatile compared to 4AB.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check 4AB.DE's competition here
AbbVie Inc. (DUS: 4AB.DU)
GS7.DE vs 4AB.DU Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, 4AB.DU has a market cap of 445.3B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while 4AB.DU trades at €252.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas 4AB.DU's P/E ratio is 44.13. In terms of profitability, GS7.DE's ROE is +0.26%, compared to 4AB.DU's ROE of -1.37%. Regarding short-term risk, GS7.DE is more volatile compared to 4AB.DU. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check 4AB.DU's competition here
Novo Nordisk A/S (XETRA: NOVC.DE)
GS7.DE vs NOVC.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, NOVC.DE has a market cap of 406.7B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while NOVC.DE trades at €91.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas NOVC.DE's P/E ratio is 22.91. In terms of profitability, GS7.DE's ROE is +0.26%, compared to NOVC.DE's ROE of +0.88%. Regarding short-term risk, GS7.DE is more volatile compared to NOVC.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check NOVC.DE's competition here
Merck & Co., Inc. (XETRA: 6MK.DE)
GS7.DE vs 6MK.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, 6MK.DE has a market cap of 335.4B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while 6MK.DE trades at €135.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas 6MK.DE's P/E ratio is 54.41. In terms of profitability, GS7.DE's ROE is +0.26%, compared to 6MK.DE's ROE of +0.07%. Regarding short-term risk, GS7.DE is more volatile compared to 6MK.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check 6MK.DE's competition here
AstraZeneca PLC (XETRA: ZEG.DE)
GS7.DE vs ZEG.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, ZEG.DE has a market cap of 249.2B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while ZEG.DE trades at €160.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas ZEG.DE's P/E ratio is 26.61. In terms of profitability, GS7.DE's ROE is +0.26%, compared to ZEG.DE's ROE of +0.22%. Regarding short-term risk, GS7.DE is more volatile compared to ZEG.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check ZEG.DE's competition here
Amgen Inc. (XETRA: AMG.DE)
GS7.DE vs AMG.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, AMG.DE has a market cap of 216.7B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while AMG.DE trades at €400.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas AMG.DE's P/E ratio is 20.79. In terms of profitability, GS7.DE's ROE is +0.26%, compared to AMG.DE's ROE of +0.89%. Regarding short-term risk, GS7.DE is more volatile compared to AMG.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check AMG.DE's competition here
Gilead Sciences, Inc. (XETRA: GIS.DE)
GS7.DE vs GIS.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, GIS.DE has a market cap of 172.3B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while GIS.DE trades at €138.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas GIS.DE's P/E ratio is -112.01. In terms of profitability, GS7.DE's ROE is +0.26%, compared to GIS.DE's ROE of -0.16%. Regarding short-term risk, GS7.DE is more volatile compared to GIS.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check GIS.DE's competition here
Novo Nordisk A/S (XETRA: NOV.DE)
GS7.DE vs NOV.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, NOV.DE has a market cap of 155.6B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while NOV.DE trades at €35.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas NOV.DE's P/E ratio is 11.30. In terms of profitability, GS7.DE's ROE is +0.26%, compared to NOV.DE's ROE of +0.59%. Regarding short-term risk, GS7.DE is more volatile compared to NOV.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check NOV.DE's competition here
Pfizer Inc. (XETRA: PFE.DE)
GS7.DE vs PFE.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, PFE.DE has a market cap of 154.2B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while PFE.DE trades at €27.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas PFE.DE's P/E ratio is 11.68. In terms of profitability, GS7.DE's ROE is +0.26%, compared to PFE.DE's ROE of +0.05%. Regarding short-term risk, GS7.DE is more volatile compared to PFE.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check PFE.DE's competition here
Bristol-Myers Squibb Company (XETRA: BRM.DE)
GS7.DE vs BRM.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, BRM.DE has a market cap of 114.6B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while BRM.DE trades at €56.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas BRM.DE's P/E ratio is 14.35. In terms of profitability, GS7.DE's ROE is +0.26%, compared to BRM.DE's ROE of +0.47%. Regarding short-term risk, GS7.DE is more volatile compared to BRM.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check BRM.DE's competition here
Sanofi (XETRA: SNW.DE)
GS7.DE vs SNW.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, SNW.DE has a market cap of 89.6B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while SNW.DE trades at €74.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas SNW.DE's P/E ratio is 23.09. In terms of profitability, GS7.DE's ROE is +0.26%, compared to SNW.DE's ROE of +0.06%. Regarding short-term risk, GS7.DE is more volatile compared to SNW.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check SNW.DE's competition here
Bayer Aktiengesellschaft (XETRA: BAYN.DE)
GS7.DE vs BAYN.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, BAYN.DE has a market cap of 43.4B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while BAYN.DE trades at €44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas BAYN.DE's P/E ratio is 9.14. In terms of profitability, GS7.DE's ROE is +0.26%, compared to BAYN.DE's ROE of -0.06%. Regarding short-term risk, GS7.DE is more volatile compared to BAYN.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check BAYN.DE's competition here
Bayer Aktiengesellschaft (STU: BAYN.SG)
GS7.DE vs BAYN.SG Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, BAYN.SG has a market cap of 43.2B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while BAYN.SG trades at €44.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas BAYN.SG's P/E ratio is -38.60. In terms of profitability, GS7.DE's ROE is +0.26%, compared to BAYN.SG's ROE of -0.06%. Regarding short-term risk, GS7.DE is more volatile compared to BAYN.SG. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check BAYN.SG's competition here
Biogen Inc. (XETRA: IDP.DE)
GS7.DE vs IDP.DE Comparison October 2026
GSK plc (XETRA: GS7.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GS7.DE stands at 0. In comparison, IDP.DE has a market cap of 24.5B. Regarding current trading prices, GS7.DE is priced at €20.60 on the XETRA, while IDP.DE trades at €165.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GS7.DE currently has a P/E ratio of 17.31, whereas IDP.DE's P/E ratio is 14.83. In terms of profitability, GS7.DE's ROE is +0.26%, compared to IDP.DE's ROE of +0.05%. Regarding short-term risk, GS7.DE is more volatile compared to IDP.DE. This indicates higher risk in terms of short-term price fluctuations for GS7.DE.Check IDP.DE's competition here